Erica J Brenner1, Millie D Long2, Courtney M Mann3, Li Lin3, Wenli Chen2, Camila Reyes4, Kirsten M Bahnson3, Bryce B Reeve3, Michael D Kappelman1. 1. Department of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. 2. Department of Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. 3. Department of Population Health Sciences, School of Medicine, Duke University, Durham, North Carolina, United States of America. 4. Office of Clinical Research, School of Medicine, Duke University, Durham, North Carolina, United States of America.
Abstract
BACKGROUND: Studies of adults with Crohn's disease (CD) suggest that poor mental health precedes worsening disease activity. We evaluated whether depression and/or anxiety forecast worsening pediatric CD disease activity. METHODS: Through the Inflammatory Bowel Disease Partners Kids & Teens internet-based cohort, children with CD age 9 to 17 completed Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric measures and the short Crohn's disease activity index (sCDAI). Using general linear models, we examined how baseline PROMIS Pediatric anxiety and depressive symptom scores independently associate with subsequent sCDAI scores (average survey interval 6.4 months). Models included baseline PROMIS Pediatric anxiety and depressive symptoms scores, baseline sCDAI, sex, age, parental education, race/ethnicity, and prior IBD-related surgery. We performed a post hoc subanalysis of children in baseline remission (sCDAI <150) with otherwise identical models. RESULTS: We analyzed 159 children with CD (mean age 14 years, 45% female, 84% in baseline remission). We found no association between baseline PROMIS Pediatric anxiety score and subsequent sCDAI (change in sCDAI for 3-point change in PROMIS Pediatric -0.89; 95% CI -4.81 to 3.03). Baseline PROMIS Pediatric depressive symptoms score was not associated with future sCDAI (change in sCDAI for 3-point change in PROMIS Pediatric <0.01; 95% CI -4.54 to 4.53). In a subanalysis of patients in remission at baseline, the lack of association remained. CONCLUSION: We found that neither anxiety nor depressive symptoms associate with subsequent disease activity in pediatric CD. These findings contrast with adult IBD studies, thus underschoring the unique pathophysiology, natural history, and outcomes of pediatric CD.
BACKGROUND: Studies of adults with Crohn's disease (CD) suggest that poor mental health precedes worsening disease activity. We evaluated whether depression and/or anxiety forecast worsening pediatric CD disease activity. METHODS: Through the Inflammatory Bowel Disease Partners Kids & Teens internet-based cohort, children with CD age 9 to 17 completed Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric measures and the short Crohn's disease activity index (sCDAI). Using general linear models, we examined how baseline PROMIS Pediatric anxiety and depressive symptom scores independently associate with subsequent sCDAI scores (average survey interval 6.4 months). Models included baseline PROMIS Pediatric anxiety and depressive symptoms scores, baseline sCDAI, sex, age, parental education, race/ethnicity, and prior IBD-related surgery. We performed a post hoc subanalysis of children in baseline remission (sCDAI <150) with otherwise identical models. RESULTS: We analyzed 159 children with CD (mean age 14 years, 45% female, 84% in baseline remission). We found no association between baseline PROMIS Pediatric anxiety score and subsequent sCDAI (change in sCDAI for 3-point change in PROMIS Pediatric -0.89; 95% CI -4.81 to 3.03). Baseline PROMIS Pediatric depressive symptoms score was not associated with future sCDAI (change in sCDAI for 3-point change in PROMIS Pediatric <0.01; 95% CI -4.54 to 4.53). In a subanalysis of patients in remission at baseline, the lack of association remained. CONCLUSION: We found that neither anxiety nor depressive symptoms associate with subsequent disease activity in pediatric CD. These findings contrast with adult IBD studies, thus underschoring the unique pathophysiology, natural history, and outcomes of pediatric CD.
Authors: Kelvin Thia; William A Faubion; Edward V Loftus; Tore Persson; Anders Persson; William J Sandborn Journal: Inflamm Bowel Dis Date: 2011-01 Impact factor: 5.325
Authors: Timothy G Brandon; Brandon D Becker; Katherine B Bevans; Pamela F Weiss Journal: Arthritis Care Res (Hoboken) Date: 2017-03 Impact factor: 4.794
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Laura C Reigada; Claire J Hoogendoorn; Lindsay C Walsh; Joanne Lai; Eva Szigethy; Barry H Cohen; Ruijun Bao; Kimberly Isola; Keith J Benkov Journal: J Pediatr Gastroenterol Nutr Date: 2015-01 Impact factor: 2.839
Authors: Debra E Irwin; Brian D Stucky; David Thissen; Esi Morgan Dewitt; Jin Shei Lai; Karin Yeatts; James W Varni; Darren A DeWalt Journal: Qual Life Res Date: 2010-03-05 Impact factor: 4.147
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: Laura M Mackner; Rachel Neff Greenley; Eva Szigethy; Michele Herzer; Kate Deer; Kevin A Hommel Journal: J Pediatr Gastroenterol Nutr Date: 2013-04 Impact factor: 2.839
Authors: Agnieszka Butwicka; Ola Olén; Henrik Larsson; Jonas Halfvarson; Catarina Almqvist; Paul Lichtenstein; Eva Serlachius; Louise Frisén; Jonas F Ludvigsson Journal: JAMA Pediatr Date: 2019-10-01 Impact factor: 16.193